FDA Mandates E2b Standard For All Icsr Submissions Via Aems Today

Pharmacovigilance teams at drug and biologics manufacturers face a hard compliance cutoff: beginning October 1, 2026, all postmarketing individual case safety reports (ICSRs) submitted through the Electronic Submissions Gateway Next Generation (ESG NextGen) must conform to E2B(R3) data standards. FDA's April 6, 2026 announcement, published at 91 FR 17284, extended the original transition deadline by six months, that extension now expires.

The mandate applies to human drug products, biological products, and drug- or biologic-led combination products routed through CDER and CBER. Companies that have already begun submitting in E2B(R3) format are expected to maintain that standard exclusively; reversion to E2B(R2) is not permitted once the transition has started. FDA will cease accepting E2B(R2)-formatted ICSRs after September 30, 2026.

The reporting infrastructure underpinning this requirement is FDA's new Adverse Event Monitoring System (AEMS), a unified platform consolidating multiple legacy reporting systems across all regulated product categories. For drug and biologics operations, AEMS replaces fragmented database-to-database transmission pathways and introduces AI-based redaction, digitization tools, and enhanced cross-product analytics. The operational implication for QA and regulatory affairs leads is direct: any database-to-database transmission pipeline not yet validated against E2B(R3) schemas requires remediation before the cutoff.

Concurrent with the AEMS rollout, FDA issued the ICH E2D(R1) guidance on March 6, 2026 (91 FR 10619), updating terminology and standards for postapproval adverse event reporting. AEMS now accepts three new values for data element C.5.4 (Study Type Where Reaction(s)/Event(s) Were Observed): Patient Support Program (value 4), Market Research Program (value 5), and Organised Data Collection System with source data from a digital platform (value 6). Pharmacovigilance system owners should confirm their ICSR generation tools are mapped to these new values ahead of October 1.

The six-month extension FDA granted in April provided additional runway for system validation and staff retraining, but that buffer is now exhausted; submissions arriving in E2B(R2) format after the deadline will fall outside FDA's accepted processing parameters under the new AEMS architecture.

The measurable compliance checkpoint is unambiguous: zero E2B(R2) ICSRs transmitted via ESG NextGen on or after October 1, 2026.

Source: FDA Drugs, What's New RSS Feed via fda.gov, September 30, 2026.